PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotechnology and life sciences enterprise dedicated to the progression of clinical development programmes involving innovative and potentially transformative therapeutic assets. The Company is pleased to report topline results from its Phase 2 clinical study (SKNJCT-003) that assessed the safety and efficacy of the Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of basal cell carcinoma (BCC) of the skin.
The topline results from this study are not only encouraging but are deemed decision-grade, indicating a strong foundation for the Company to engage in an End of Phase 2 (EOP2) meeting with the FDA in the first half of 2026. Furthermore, these findings are expected to expedite the Company’s readiness for potential partnerships.